Your browser doesn't support javascript.
loading
Grade Group 1 Prostate Cancers Exhibit Tumor-defining Androgen Receptor-driven Programs.
Linder, Simon; Severson, Tesa M; van der Mijn, Koen J C; Nevedomskaya, Ekaterina; Siefert, Joseph C; Stelloo, Suzan; Pomerantz, Mark M; Freedman, Matthew L; van der Poel, Henk; Jerónimo, Carmen; Henrique, Rui; Bergman, Andries M; Zwart, Wilbert.
Afiliación
  • Linder S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Severson TM; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Mijn KJC; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Nevedomskaya E; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Siefert JC; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Stelloo S; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Pomerantz MM; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Freedman ML; The Eli and Edythe L. Broad Institute, Cambridge, MA, USA; Division of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van der Poel H; Division of Urology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Department of Urology, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Jerónimo C; Cancer Biology and Epigenetics Group, Research Center of the Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, Univer
  • Henrique R; Cancer Biology and Epigenetics Group, Research Center of the Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology, Portuguese Oncology Institute of Porto, Porto, Portugal; Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, Univer
  • Bergman AM; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: a.bergman@nki.nl.
  • Zwart W; Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands. Electronic addre
Eur Urol ; 84(5): 455-460, 2023 11.
Article en En | MEDLINE | ID: mdl-37271632
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Receptores Androgénicos Límite: Humans / Male Idioma: En Revista: Eur Urol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Receptores Androgénicos Límite: Humans / Male Idioma: En Revista: Eur Urol Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos